The Journal for ImmunoTherapy of Cancer (JITC) is the official journal of the Society for Immunotherapy of Cancer (SITC). This open access, peer-reviewed journal not only serves as the global voice of the society, but also a targeted outlet for the publication of original research articles, literature reviews, position papers and discussion on all aspects of tumor immunology and cancer immunotherapy—from basic research to clinical application.
Today, more than ever before, the tremendous excitement in the field and the increased momentum brought about by the latest approvals of immunotherapy-based treatments in various cancer types has shown the clear need for the Journal for ImmunoTherapy of Cancer, an outlet devoted to and created by today's leaders in the field.
Read the Journal for ImmunoTherapy of Cancer (JITC)
As a way to thank the dedicated society members who tirelessly work to advance the science and ultimately to improve the lives of patients with cancer, SITC is pleased to offer society members waived article processing charges for manuscripts accepted through 2018.
To take advantage of this member benefit, contact SITC at +1 414-271-2456 or JITCEditor@sitcancer.org for your member code.
Indicated below by a circular image near the author listings, the Altmetric Attention Score for research outputs provides an indicator of the amount of attention an article has received. The score is derived from an automated algorithm, and represents a weighted count of the amount of attention picked up for a research output. Learn more here.
The use of immunomodulation to treat malignancies has seen a recent explosion in interest. The therapeutic appeal of these treatments is far reaching, and many new applications continue to evolve. In particular, immune modulating drugs have the potential to enhance the systemic anticancer immune effects induced by locoregional thermal ablation. The immune responses induced by ablation monotherapy are well documented, but independently they tend to be incapable of evoking a robust antitumor response. By adding immunomodulators to traditional ablative techniques, several researchers have sought to amplify the induced immune response and trigger systemic antitumor activity. This paper summarizes the work done in animal models to investigate the immune effects induced by the combination of ablative therapy and immunomodulation. Combination therapy with radiofrequency ablation, cryoablation, and microwave ablation are all reviewed, and special attention has been paid to the addition of checkpoint blockades.
Metastatic disease is the leading cause of death among cancer patients and involves a complex and inefficient process. Every step of the metastatic process can be rate limiting and is influenced by non-malignant host cells interacting with the tumor cell. Over a century ago, experiments first indicated a link between the immune system and metastasis. This phenomenon, called concomitant immunity, indicates that the primary tumor induces an immune response, which may not be sufficient to destroy the primary tumor, but prevents the growth of a secondary tumor or metastases. Since that time, many different immune cells have been shown to play a role in both inhibiting and promoting metastatic disease. Here we review classic and new observations, describing the links between the immune system and metastasis that inform the development of cancer therapies.
This message was posted by a user wishing to remain anonymous Hi All His is an attempt to find answers on the observed onset of effect on Opdivo / Nivolumab treatment. If you are a doctor having experience with this treatment I would be eager to hear ...
What's new in immuno-oncology? Discover the latest advancements in combination immunotherapy in this interview with James Gulley in which he provides insider details of the Phase I trial for M7824. www.oncology-central.com/2017/11/22/whats-new-immuno-oncology-interview-james-gulley/ ...
The publication yesterday of the first clinical guidelines by the Society for Immunotherapy of Cancer on management of side effects associated with immunotherapies really felt momentous. We've been talking about these issues for a couple of years ...
It was great seeing old friends again and meeting new ones at the 32 nd Annual Meeting & Pre-Conference Programs in National Harbor! We appreciate all who joined SITC for our most successful Annual Meeting yet and hope you had a great time learning, ...
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: email@example.com